Small fatty molecules may predict future relapse risk in early MS, study suggests

Research published in the Journal of Neurology, Neurosurgery & Psychiatry identifies specific lipid biomarkers that could help predict relapse risk in patients with early-stage multiple sclerosis (MS), according to a study led by researchers at the University of California, San Francisco. The findings, which analyzed blood samples from 240 participants, highlight the potential for early intervention strategies.

Study details and key findings

The study, conducted between 2018 and 2022, tracked patients diagnosed with relapsing-remitting MS within the first two years of symptom onset. Researchers identified 12 fatty acid derivatives in blood samples that correlated with a higher likelihood of relapse within 18 months, as reported by the Journal of Neurology, Neurosurgery & Psychiatry. These molecules, including lysophosphatidylcholines and ceramides, were found in elevated levels in patients who experienced relapses compared to those who remained stable.

“These lipids may serve as early warning signals,” said Dr. Emily Carter, a neurologist at UCSF and co-author of the study. “If validated in larger trials, they could help clinicians tailor treatments to high-risk patients before symptoms worsen.” The research team used mass spectrometry to measure lipid profiles, ensuring precise quantification of the compounds.

Implications for treatment and diagnosis

The discovery could reshape MS management by enabling earlier, more personalized care. Current diagnostic tools rely on MRI scans and clinical symptoms, which may not detect relapse risk until after disease progression. The lipid biomarkers offer a noninvasive blood test alternative, according to the study.

The National MS Society, which funded part of the research, emphasized the potential impact. “Identifying biomarkers that predict disease activity is a critical step toward precision medicine,” said Dr. Michael Thompson, director of research at the society. “This work underscores the importance of biomarker-driven approaches in MS care.”

Limitations and next steps

While the study’s sample size was robust, researchers noted the need for larger, multi-center trials to confirm the findings. The team is currently collaborating with institutions in Europe and Asia to validate the lipid biomarkers across diverse populations, as reported by Neurology Today.

“We’re cautious but optimistic,” said Dr. Carter. “These results are a starting point, not a definitive answer. Replication is essential before clinical adoption.” The study’s authors also called for further investigation into how these lipids interact with immune responses in MS.

What does this mean for patients?

For patients, the findings could lead to more proactive treatment plans. Early intervention with disease-modifying therapies has been shown to reduce long-term disability, but identifying high-risk individuals remains a challenge. The lipid test, if approved, could be integrated into routine checkups, according to the study.

“This isn’t a cure, but it’s a tool,” said Dr. Thompson. “It gives doctors more information to make decisions that could improve quality of life.” The study’s authors also highlighted the need for patient education to ensure informed use of the test.

Comparative context

This research aligns with other recent studies exploring biomarkers in MS. A 2023 study in Nature Neuroscience identified similar metabolic changes in MS patients, though it focused on brain tissue rather than blood. The UCSF study’s emphasis on blood-based markers makes it more accessible for widespread use, according to experts.

However, some researchers caution against overinterpreting the results. “Biomarkers are complex,” said Dr. Sarah Lin, a neuroimmunologist at Johns Hopkins University, who was not involved in the study. “Correlation doesn’t always mean causation, and more research is needed to understand their clinical relevance.”

Future outlook

The next phase of research will focus on longitudinal studies to track how lipid levels change over time and whether interventions targeting these molecules can reduce relapse rates. The study’s authors also plan to explore connections between the biomarkers and genetic factors, as noted in their paper.

As the field of MS research advances, the integration of lipid biomarkers into clinical practice could mark a significant shift in how the disease is managed. For now, the findings offer a promising glimpse into the future of personalized medicine for MS patients.